Human Erythropoietin/EPO Quantikine ELISA Kit, RUO Best Seller
R&D Systems, part of Bio-Techne | Catalog # DEPRU0
Key Product Details
Assay Length
4.5 hours (Benchtop Protocol) or 2.5 hours (Shaker Protocol)
Sample Type & Volume Required Per Well
Serum (100 µL), EDTA Plasma (100 µL)
Sensitivity
0.6 mIU/mL
Assay Range
2.5-200 mIU/mL (Serum, EDTA Plasma)
Product Summary for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO
The Quantikine® Human Epo ELISA uses a monoclonal antibody and polyclonal antibody conjugate in a sandwich ELISA format. The assay is designed to measure Epo levels in serum or EDTA plasma in less than 4.5 hours, or less than 2.5 hours using the shaker protocol.
Product Specifications
Measurement
Quantitative ELISA
Detection Method
Colorimetric - 450nm (TMB)
Conjugate
HRP
Reactivity
Human
Specificity
Natural and recombinant human Epo.
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules. < 50% cross-species reactivity observed with species tested.
Interference
Interference observed with other substances.
Sample Values
Samples from apparently healthy volunteers were evaluated for the presence of human Epo in
this assay. No medical histories were available for the donors used in this study.
| Serum (n=123) | EDTA plasma (n=123) |
| 3.3-16.6 mIU/mL | 3.1-14.9 mIU/mL |
Precision
Intra-Assay Precision (Precision within an assay) Four samples of known concentration were tested thirty times to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Four samples of known concentration were tested in thirty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using three lots of components.
EDTA Plasma, Serum
| Intra-Assay Precision | Inter-Assay Precision | |||||||
|---|---|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| n | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Mean (mIU/mL) | 5.82 | 16.01 | 25.18 | 79.02 | 6.45 | 16.22 | 26.35 | 84.14 |
| Standard Deviation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CV% | 8.25 | 4.30 | 5.90 | 4.24 | 10.30 | 3.74 | 4.20 | 3.71 |
Recovery for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO
The recovery of human Epo spiked to levels throughout the range of the assay was evaluated in 10 serum and plasma samples.
| Specimen Type | Protocol | Amount Needed | Mean Recovery |
| Serum | Benchtop | 52.2 mlU/mL | 100% |
| Shaker | 57.5 mlU/mL | 93% | |
| Plasma (EDTA) | Benchtop | 51.8 mlU/mL | 102% |
| Shaker | 55.9 mlU/mL | 105% |
Linearity
Five matched serum and plasma specimens containing elevated Epo concentrations were diluted with Specimen Diluent and assayed using the Quantikine Human Epo ELISA. Diluted specimens demonstrated very good linearity when compared to neat concentrations of Epo.
Scientific Data Images for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO
Human Epo ELISA Benchtop Protocol Standard Curve
Human Epo ELISA Shaker Protocol Standard Curve
Preparation and Storage
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: Erythropoietin/EPO
The over-expression of Epo may be associated with certain pathophysiological conditions (1,
2). Polycythemia exists when there is an overproduction of red blood cells (RBCs). Primary
polycythemias, such as polycythemia vera, are caused by Epo-independent growth of
erythrocytic progenitors from abnormal stem cells and low to normal levels of Epo are found in
the serum of affected patients. On the other hand, various types of secondary polycythemias
are associated with the production of higher than normal levels of Epo. The overproduction of
Epo may be an adaptive response associated with conditions that produce tissue hypoxia, such
as living at high altitude, chronic obstructive pulmonary disease, cyanotic heart disease, sleep
apnea, high-affinity hemoglobinopathy, smoking, or localized renal hypoxia (1, 2). In other
instances, excessive Epo levels are the result of production by neoplastic cells. Cases of
increased Epo production and erythrocytosis have been reported for patients with renal
carcinomas (3), benign renal tumors (4), Wilms' tumors, hepatomas (5), liver carcinomas (6),
cerebellar hemangioblastomas (3, 7, 8), adrenal gland tumors (9), smooth muscle tumors (3, 9),
and leiomyomas (10).
Deficient Epo production is found in conjunction with certain forms of anemias. These include
anemia of renal failure and end-stage renal disease (1, 2, 11), anemias of chronic disorders
[chronic infections (1), autoimmune diseases (1), rheumatoid arthritis (12), AIDS (13),
malignancies (14)], anemia of prematurity (2), anemia of hypothyroidism (2), and anemia of
malnutrition (2). Many of these conditions are associated with the generation of IL-1 and TNF-alpha,
factors that have been shown to be inhibitors of Epo activity (1, 15). Other forms of anemias, on
the other hand, are due to Epo-independent causes and affected individuals show elevated
levels of Epo (2). These forms include aplastic anemias, iron deficiency anemias, thalassemias,
megaloblastic anemias, pure red cell aplasias, and myelodysplastic syndromes.
Alternate Names
ECYT5, EPO, MVCD2
Gene Symbol
EPO
Additional Erythropoietin/EPO Products
Product Documents for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO
Product Specific Notices for Human Erythropoietin/EPO Quantikine ELISA Kit, RUO
For research use only
Loading...
Loading...
Loading...
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.